A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options

• DOI: 10.1016/j.yexmp.2022.104832
• Publication Date: 2022-09-17T12:31:17Z
• Authors: Weijie Xue; Bingzi Dong; Yixiu Wang; Yuwei Xie; Pu Li; Zhiqi Gong; Zhaojian Niu
• Keywords: 0301 basic medicine; 03 medical and health sciences; Stomach Neoplasms; Tumor Microenvironment; Humans; Immunotherapy; Adenocarcinoma; Prognosis; Immune Checkpoint Inhibitors; 3. Good health

Stomach adenocarcinoma (STAD) is one of the most common malignant tumors worldwide. In this study, we attempted to construct a valid immune-associated gene prognostic index risk model that can predict the survival of patients with STAD and the efficacy of immune checkpoint inhibitors (ICIs) treatment. Transcriptome, clinical, and gene mutational data were obtained from the TCGA database. Immune-related genes were downloaded from the ImmPort and InnateDB databases. A total of 493 immune-related genes were identified to be enriched in functions associated with immune response, as well as in immune and tumor-related pathways. Further, 36 candidate genes related to the overall survival (OS) of STAD were obtained by weighted gene co-expression network analysis (WGCNA). Next, based on a Cox regression analysis, we constructed an immune-associated gene prognostic index (IAGPI) risk model based on eight genes, which was verified using the GEO STAD cohort. The patients were divided into two subsets according to their risk score. Patients in the low-risk group had better OS than those in the high-risk group. In the low-risk group, there were more CD8, activated memory CD4, and follicular helper T cells, and M1 macrophages, whereas monocytes, M2 macrophages, eosinophils, and neutrophils were more abundant in the high-risk group. The patients in the low-risk group were more sensitive to ICIs therapy. The IAGPI risk model can precisely predict the prognosis, reflect the tumor immune microenvironment, and predict the efficacy of ICIs therapy in patients with STAD.